065650 — Medifron DBT Co Share Price
Last trade - 00:00- KR₩91bn
- KR₩81bn
- KR₩52bn
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 2.47 | ||
| Price to Tang. Book | 2.5 | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | 1.75 | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -3.49% | ||
| Return on Equity | -5.77% | ||
| Operating Margin | -2.59% | ||
Financial Summary
| Year End 31st Dec | Unit | 2019 | 2020 | 2021 | 2022 | 2023 | 2024E | 2025E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | KR₩m | 17,412.91 | 30,190.15 | 49,250.94 | 45,289.9 | 52,042.01 | n/a | n/a | 21.21% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Medifron DBT Co., Ltd. is a Korea-based company mainly engaged in the production and sale of telecommunication equipments. The Company operates its business through two segments. The Information Technology Business segment is involved in the manufacturing and sale of mouses, monitors, televisions (TVs), routers and game devices. In addition, it is involved in the operation of Internet portals and specialized sites. The New Drug Business segment is engaged in the development and sale of non narcotic analgesics, Alzheimer's treatments, and Alzheimer's dementia diagnosis kits.
Directors
- Gi Seon Noh CEO (55)
- Hyeon Sang Mook CCE (54)
- Seong Jun Shin OTH (46)
- Dong Beom Yim DRC (49)
- Jong Mo Kim NID (48)
- Last Annual
- December 31st, 2023
- Last Interim
- December 31st, 2023
- Incorporated
- March 18th, 1997
- Public Since
- January 21st, 2003
- No. of Shareholders
- 19,227
- No. of Employees
- 67
- Sector
- Computers, Phones & Household Electronics
- Industry
- Technology
- Exchange
- Korea Exchange - KOSDAQ
- Shares in Issue
- 63,153,285
- Address
- 517, 5F, A Dong, Jeiplatz, 186, Gasan di, SEOUL, 08502
- Web
- https://www.medifron.com/ko/index.asp
- Phone
- +82 25459277
- Auditors
- Yekyo Jisung Accounting Corporation
Upcoming Events for 065650
Similar to 065650
Abko Co
Korea Exchange - KOSDAQ
Atec Co
Korea Exchange - KOSDAQ
Atec Mobility Co
Korea Exchange - KOSDAQ
Cots Technology Co
Korea Exchange - KOSDAQ
Digital Graphics
Korea Exchange - KOSDAQ
FAQ
As of Today at 19:14 UTC, shares in Medifron DBT Co are trading at KR₩1,443. This share price information is delayed by 15 minutes.
Shares in Medifron DBT Co last closed at KR₩1,443 and the price had moved by +12.54% over the past 365 days. In terms of relative price strength the Medifron DBT Co share price has outperformed the FTSE Developed Asia Pacific Index by +12.65% over the past year.
There is no consensus recommendation for this security.
Medifron DBT Co does not currently pay a dividend.
Medifron DBT Co does not currently pay a dividend.
Medifron DBT Co does not currently pay a dividend.
To buy shares in Medifron DBT Co you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
As of the previous close price of KR₩1,443, shares in Medifron DBT Co had a market capitalisation of KR₩91bn.
Here are the trading details for Medifron DBT Co:
- Country of listing: Korea, Republic of
- Exchange: KOE
- Ticker Symbol: 065650
Based on an overall assessment of its quality, value and momentum Medifron DBT Co is currently classified as a Sucker Stock. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
We could not find analyst target price data for this security.
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Medifron DBT Co. Over the past six months, its share price has outperformed the FTSE Developed Asia Pacific Index by +30.61%.
As of the last closing price of KR₩1,443, shares in Medifron DBT Co were trading +18.91% higher than their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
The Medifron DBT Co PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at KR₩1,443.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Medifron DBT Co's management team is headed by:
- Gi Seon Noh - CEO
- Hyeon Sang Mook - CCE
- Seong Jun Shin - OTH
- Dong Beom Yim - DRC
- Jong Mo Kim - NID